Inovio Pharmaceuticals, Inc. (INO)
| Previous close | 10.16 |
| Open | 10.17 |
| Bid | 10.24 x 200 |
| Ask | 10.42 x 200 |
| Day's range | 10.14 - 10.36 |
| 52-week range | 3.84 - 14.75 |
| Volume | |
| Avg. volume | 423,790 |
| Market cap | 266.88M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.51 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.92 |
PR NewswireINOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc.
PR NewswireINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- GuruFocus.com
Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
